Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Jumped Today

By Keith Speights - Feb 19, 2021 at 3:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's hepatitis B virus vaccine won European Union approval.

What happened

Shares of Dynavax Technologies (DVAX 0.41%) were jumping 5.9% higher as of 3:09 p.m. EST on Friday. The gain came after the company announced that its hepatitis B virus (HBV) vaccine Heplisav-B received marketing authorization from the European Commission (EC).

So what

Today's news wasn't really a surprise. The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) already gave a positive approval recommendation. Heplisav-B is also already approved in the U.S.

Gloved fingers holding a syringe with a label stating "Hepatitis B."

Image source: Getty Images.

However, the announcement removed one more hurdle for Dynavax. Its HBV vaccine is now approved throughout all 28 countries in the European Union (EU). The EC marketing authorization is also valid in Iceland, Liechtenstein, and Norway, which aren't members of the EU.

The regulatory authorization will greatly expand Dynavax's potential market. There are over 250 million people infected with HBV worldwide. Around 15 million of those individuals live in Europe.

Now what

Dynavax expects to launch Heplisav-B in Europe later this year. The next potential catalyst for the biotech stock, though, could be only a few days away. Dynavax is scheduled to announce its fourth-quarter and full-year 2020 results on Feb. 25. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$12.33 (0.41%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.